Blue­bird gets PDU­FA date for lo­vo-cel; FDA lifts hold on Di­aMed­ica stroke tri­al

The FDA has ac­cept­ed the BLA from blue­bird bio for its gene ther­a­py lovotibeglo­gene au­totem­cel, or lo­vo-cel, de­signed to treat pa­tients with sick­le cell dis­ease (SCD) who have a his­to­ry of va­so-oc­clu­sive events.

Blue­bird an­nounced Wednes­day that the agency set the PDU­FA date for Dec. 20. The ap­pli­ca­tion is based on ef­fi­ca­cy re­sults from 36 pa­tients in one study co­hort that had 32 months of fol­low-up ex­am­i­na­tions, and an­oth­er group of two pa­tients that had 18 months of fol­low-up. The sub­mis­sion al­so has safe­ty da­ta from 50 pa­tients which in­clude six pa­tients that have had over six years of fol­low-up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER